Angiotech Pharmaceuticals, Inc. (USA) (NASDAQ:ANPI)

Fedyzer (63.80) Submitted: 8/12/2007 5:17:58 PM : Start Price: $6.27 ANPI Score: -91.55

several of their products could be disruptive technology

iknowhow2trade (< 20) Submitted: 6/4/2007 9:38:57 PM : Start Price: $6.93 ANPI Score: -87.79

very cheap should go abck to $9

koshermafia (< 20) Submitted: 4/2/2007 5:35:54 PM : Start Price: $5.39 ANPI Score: -93.76

A recent study on stents sent the stock down to a 52 week low. However one study a trend does not make and looking at their financial outlook shows promising strength.

junkbondsman (< 20) Submitted: 3/4/2007 1:21:43 PM : Start Price: $6.47 ANPI Score: -98.39

reportedly top notch vp of research, negatives about drug eluting stents are still out weighed by positives, peripheral use is another question

flexnexus (< 20) Submitted: 3/1/2007 11:16:42 AM : Start Price: $6.54 ANPI Score: -96.69

product pipeline bet. The debt is concerning though.

icon149 (99.53) Submitted: 2/28/2007 10:33:00 AM : Start Price: $6.65 ANPI Score: -96.27

Morningstar rec

taimura (80.58) Submitted: 2/25/2007 2:34:17 AM : Start Price: $6.96 ANPI Score: -93.11

low valuation

Tedgerstl (< 20) Submitted: 2/13/2007 2:30:18 PM : Start Price: $6.71 ANPI Score: -94.00

This company is mistakenly seen as a

hardwareace (< 20) Submitted: 2/1/2007 11:36:25 PM : Start Price: $8.23 ANPI Score: -94.31

Undervalued. Possible takeover candidate.

pennysplants (99.55) Submitted: 1/5/2007 1:04:38 PM : Start Price: $7.94 ANPI Score: -96.75

M* Fair = $16 ... Buy = $10. Stub is at 52-week low. Coating medical devices... growing potential market from the critical (stents) to the mundane (sutures). Acquisition of AMI may be transformational. Tied to another of my CAPS picks (VITA). EBITA margins 40% ????

Watch Out! The cloud of coated stents is still playing havoc with JNJ, Boston Scientific and ANPI. Concern: Taxus stent still equals 50% of ANPI's business. Management effectiveness (NOT science) will be the key to this play. AMI put debt on the balance sheet ... and taxus sales are under severe pressure.

While speculative, I feel comfortable at this margin of safety.

jazper293 (< 20) Submitted: 1/4/2007 3:39:48 PM : Start Price: $8.02 ANPI Score: +96.53

down

aati (30.42) Submitted: 11/17/2006 9:42:44 PM : Start Price: $8.35 ANPI Score: -97.57

Angiotech Pharmaceuticals is adding sales and manufacturing capabilities plus a diverse array of medical devices that can combine with numerous pharmaceutical compounds, thanks to its purchase of AMI. Angiotech benefits greatly from Boston Scientific's focus on Taxus stent, providing a large stream of fee-based revenue for Angiotech. The company's recent acquisiton of Contour Thread will revolutionalize common cosmetic procedures, such as face lifts and breast enhancement, providing an effective minimally invasive procedure.

Angiotech's revenue base nearly doubled from its recent AMI acquisition. While the profit margins will decrease significantly due to AMI's lower margin products, combined EBITDA margins will continue to remain near the 40% level. Also, capital expenditures in the coming years is expected to remain low between 3-7% as a percentage of sales. The company may continue to pursue acquisitions. But only small ones are anticipated. Therefore, margins should stabilize in the coming years.

Target price: $16.00
52 Wk High: $16.80 (-50.5%)
52 Wk Low: $8.00 (4.0%)

snoopyj (< 20) Submitted: 11/17/2006 4:42:26 PM : Start Price: $8.35 ANPI Score: -97.66

Angiotech Pharmaceuticals is adding sales and manufacturing capabilities plus a diverse array of medical devices that can combine with numerous pharmaceutical compounds, thanks to its purchase of AMI. Angiotech benefits greatly from Boston Scientific's focus on Taxus stent, providing a large stream of fee-based revenue for Angiotech. The company's recent acquisiton of Contour Thread will revolutionalize common cosmetic procedures, such as face lifts and breast enhancement, providing an effective minimally invasive procedure.

Angiotech's revenue base nearly doubled from its recent AMI acquisition. While the profit margins will decrease significantly due to AMI's lower margin products, combined EBITDA margins will continue to remain near the 40% level. Also, capital expenditures in the coming years is expected to remain low between 3-7% as a percentage of sales. The company may continue to pursue acquisitions. But only small ones are anticipated. Therefore, margins should stabilize in the coming years.

Target price: $16.00
52 Wk High: $16.80 (-50.5%)
52 Wk Low: $8.00 (4.0%)

Ordo (31.38) Submitted: 10/17/2006 3:30:54 PM : Start Price: $8.66 ANPI Score: -100.54

Doomsday scenario priced in, institutions chopped more off of Angiotech when Boston Scientiffic warned than they shaved off of Boston Scientiffic, even though stent only account for around 50% of its revenues at this point.